We are live on ! Find out more
STRO icon

Sutro Biopharma
STRO

112 hedge funds and large institutions have $40M invested in Sutro Biopharma in 2025 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 38 increasing their positions, 33 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

30% more call options, than puts

Call options by funds: $35K | Put options by funds: $27K

15% more repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 33

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

0.41% less ownership

Funds ownership: 7.75% → 7.34% (-0.41%)

8% less funds holding

Funds holding: 122 → 112 (-10)

37% less first-time investments, than exits

New positions opened: 17 | Existing positions closed: 27

66% less capital invested

Capital invested by funds: $118M → $40M (-$77.6M)

Holders
112
Holders Change
-10
Holders Change %
-8.2%
% of All Funds
1.5%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
17
Increased
38
Reduced
33
Closed
27
Calls
$35K
Puts
$27K
Net Calls
+$8K
Net Calls Change
-$168K

Top Buyers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
+$6.98M
2
KCM
Kynam Capital Management
New Jersey
+$2.83M
3
EP
Eversept Partners
New York
+$2.52M
4
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$2.18M
5
AQR Capital Management
AQR Capital Management
Connecticut
+$1.9M

Top Sellers

Rank Fund Capital Flow
1
Point72 Asset Management
Point72 Asset Management
Connecticut
-$4.04M
2
MB
MPM BioImpact
Massachusetts
-$3.97M
3
Citadel Advisors
Citadel Advisors
Florida
-$3.65M
4
PHP
Parkman Healthcare Partners
Connecticut
-$3.18M
5
BlackRock
BlackRock
New York
-$2.19M
Name Holding Trade Value Shares
Change 		Change in
Stake
AC
126
Aristides Capital
Kentucky
– -$146K -7,940 Closed
Baillie Gifford & Co
127
Baillie Gifford & Co
United Kingdom
– -$89.8K -4,879 Closed
MIM
128
MetLife Investment Management
New Jersey
– -$43K -2,339 Closed
DTL
129
Dynamic Technology Lab
Singapore
– -$26K -1,431 Closed
FMWA
130
Forvis Mazars Wealth Advisors
Missouri
– -$23.6K -1,284 Closed
Simplex Trading
131
Simplex Trading
Illinois
– -$2.13K -135 Closed
RS
132
R Squared
Hong Kong
– -$2.19K -119 Closed
BIG
133
Brooklyn Investment Group
New York
– -$2.09K -114 Closed
SAM
134
Smartleaf Asset Management
Massachusetts
– -$945 -51 Closed
ACM
135
Aquilo Capital Management
California
– -$916 -50 Closed
CIAM
136
Caitong International Asset Management
Hong Kong
– -$644 -35 Closed
Nisa Investment Advisors
137
Nisa Investment Advisors
Missouri
– -$107 -6 Closed
AF
138
Allworth Financial
California
– -$99 -5 Closed
IA
139
IFP Advisors
Florida
– -$55 -3 Closed
FFA
140
Farther Finance Advisors
California
– -$17 -1 Closed
2 3 4 5
6

STRO Hedge Fund Activity: Q1 2025 in Review

112 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Sutro Biopharma (STRO) for Q1 2025, worth a combined $40M — down 66% from $118M a quarter earlier.

Sellers outnumbered buyers: 27 funds closed out of STRO and 17 opened new positions — a net loss of 10 holders — while 33 trimmed existing stakes and 38 added.

The largest buyer was RA Capital Management, opening a new position worth an estimated $6.98M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $4.04M sold.

  • 112 institutional investors held Sutro Biopharma (STRO) as of Q1 2025, down from 122 in Q4 2024.
  • Funds reported $40M of Sutro Biopharma stock for Q1 2025, down 66% quarter-over-quarter.
  • 17 funds opened new Sutro Biopharma positions in Q1 2025 and 27 closed out, a net change of -10 holders.
  • The largest Sutro Biopharma buyer in Q1 2025 was RA Capital Management, an estimated $6.98M added.
  • The largest Sutro Biopharma seller in Q1 2025 was Point72 Asset Management, an estimated $4.04M sold.

Based on aggregated 13F filings for Q1 2025.